Drug Database
IM

immune globulin intravenous (Iveegam, Immuno / Iveegam EN)

✓ Approved

Baxter International, Inc. · 多克隆抗体 · 多克隆抗体

什么是 immune globulin intravenous?

immune globulin intravenous 是一种多克隆抗体,由Baxter International, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Iveegam, Immuno, Iveegam EN
公司Baxter International, Inc.
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

immune globulin intravenous 针对 5 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersSelective IgG subclass deficiency✓ Approved
Infections and infestationsBorna virus infection✓ Approved
Musculoskeletal and connective tissue disordersDermatomyositisPreclinical
Musculoskeletal and connective tissue disordersPolymyositisPreclinical
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritisPreclinical

相关研究文献

PubMedVeterinary medicine and science2026-11-19

Early Changes in Serum Protein Electrophoresis and Gamma Globulin during Initial 4 Weeks of Remdesivir Therapy in FIP Cats.

Khalili Kosar K, Cheraghi Hadi H, Saljooghian Isfahani Mohammad Hossein MH

Feline infectious peritonitis (FIP) is a fatal multisystem inflammatory disorder of cats that was historically considered untreatable before the emergence of direct-acting antivirals. The objective of the study was to evaluate early serial changes in serum protein electrophoresis (SPE) patterns in cats treated with remdesivir for FIP, emphasizing gamma-globulin concentrations and percentages. Animals included eighteen client-owned cats diagnosed with FIP based on clinical presentation, standard clinicopathological profiles, and confirmatory RT-PCR. Cats received remdesivir for 4 weeks and were monitored weekly through clinical examinations and laboratory evaluations. Blood samples were collected at baseline (prior to treatment initiation) and weekly for 4 weeks. The SPE analyzed the blood taken every week for the serum protein fractions, such as albumin and the different globulins, namely α1-, α2-, β1-, β2-, and γ-globulins. The albumin to globulin ratio (A/G ratio) was also determined. Gamma globulins were found to be significantly reduced from a median of 3.1 g/dL at week 2 to a median of 2.2 g/dL at the end of week 4 (p < .05) in cats that showed clinical response. Notably, ROC curve analysis identified that a gamma-globulin percentage <23% at week 4 and 18.96% by week 6 (AUC = 0.9105) was strongly associated with complete clinical recovery and sustained relapse-free remission. Serial monitoring of serum protein electrophoresis, particularly longitudinal trends in gamma-globulin percentages and the A/G ratio, provides an objective, practical biomarker strategy to evaluate treatment response and guide the safe timing of antiviral therapy cessation in cats with FIP.

PMID 43052221
阅读全文 →
PubMedCancer immunology, immunotherapy : CII2026-11-19

A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms.

Otoukesh Salman S, Psaila Bethan B, Kuykendall Andrew A, Gerds Aaron T AT et al.

Disease-specific somatic mutations (mut) in calreticulin (CALR) and JAK2 (JAK2V617F) are drivers of myeloproliferative neoplasms (MPNs), causing generation of immunogenic peptide epitopes hypothesized to be vaccine-targetable neoantigens. VAC85135, a heterologous prime-boost vaccine regimen comprising adenoviral and vaccinia vectors encoding polypeptides specific to mutCALR and JAK2V617F, concurrent with anti-CTLA-4, ipilimumab, was investigated in a phase 1 study. Fourteen (myelofibrosis [MF], n = 10, essential thrombocythemia [ET], n = 4; mutCALR, n = 12, JAK2V617F, n = 2) patients were enrolled across three cohorts. A safety lead-in cohort (C0) received VAC85135 alone by intramuscular injection. Following acceptable tolerability, intramuscular VAC85135 was co-administered with intravenous ipilimumab: 1 mg/kg (C1) or 3 mg/kg (C2). Antigen-specific T-cell immune responses were analyzed by IFN-γ ELISpot. Clinical responses were evaluated per IWG-MRT-ELN criteria. Treatment-related adverse events were reported in 64.3% of patients; mostly Grade 1/2. Positive immune responses to mutCALR were observed post-vaccination in 5/14 (35.7%) patients. Immune response was maintained in one C0 patient over the treatment duration starting after dose 3; responses in four C1 patients were transient and observed after dose 7 in 2/4 patients. No patients had reduced mutCALR or JAK2V617F mutant allele burden at any post-vaccination timepoint. Consistent reductions in reticulin fibrosis were not observed in post-vaccination bone marrow biopsies. Best overall response was stable disease in nine patients with MF and no response in four patients with ET. The absence or delayed onset of immune response in most patients suggest VAC85135 was poorly immunogenic and unable to generate productive CALR or JAK2 neoantigen antitumor immunity.ClinicalTrials.gov identifier: NCT05444530.

PMID 43052517
阅读全文 →
PubMedJournal of medical case reports2026-11-19

Progressive multifocal leukoencephalopathy in a 15-year-old boy with X-linked hyper-IgM syndrome: a case report.

Delavari Saeedeh S, Pourvali Ali A, Akbari Mehran M, Vajdian Shiva S et al.

Progressive multifocal leukoencephalopathy (PML) is a rare and potentially fatal infection caused by JC polyomavirus, primarily affecting individuals with impaired cellular immunity. We report a 15-year-old boy with genetically confirmed X-linked hyper-IgM syndrome due to a pathogenic CD40LG variant. Despite regular intravenous immunoglobulin replacement therapy and antimicrobial prophylaxis, he developed concurrent Pneumocystis jirovecii pneumonia and COVID-19. Approximately 2 months after recovery from the pulmonary infections, he developed progressive visual impairment, diplopia, impaired concentration, and mild generalized weakness. Brain magnetic resonance imaging revealed extensive bilateral temporo-parieto-occipital white-matter lesions. Cerebrospinal fluid polymerase chain reaction was positive for JC polyomavirus DNA, confirming the diagnosis of PML; HIV testing was negative. In the absence of an established antiviral therapy, a single intravenous dose of pembrolizumab (80 mg) was administered as an experimental immune-based intervention. Three weeks later, the patient developed rapidly progressive generalized muscle weakness and respiratory failure requiring intensive care and mechanical ventilation. Despite intensive supportive treatment, he subsequently died. The precise cause of this deterioration could not be conclusively established, and a multifactorial process involving progression of PML and treatment-related or critical-illness complications could not be excluded. PML should be considered in patients with X-linked hyper-IgM syndrome who develop new neurological manifestations. Pembrolizumab remains an experimental intervention in this setting, with uncertain efficacy and safety in primary immunodeficiency.

PMID 43053104
阅读全文 →
PubMedBMC cancer2026-11-19

Immune activation following envafolimab plus endostar in advanced non-small cell lung cancer: a retrospective, single-arm study.

Wang Yuanyong Y, Ding Lu L, Liu Jiaming J, Wang Maolong M et al.

Immune checkpoint inhibitors (ICIs) are a key therapeutic approach for advanced non‑small cell lung cancer (NSCLC). However, many patients experience limited benefits, primarily due to acquired resistance. Envafolimab, a subcutaneous PD‑L1 inhibitor, and endostar, a recombinant human endostatin, may exert synergistic anti-tumor effects through immune activation and vascular normalization. This study investigated the effectiveness and safety of envafolimab combined with endostar in patients with advanced NSCLC, including a subgroup that progressed after previous anti-PD-1/PD-L1 therapy. This retrospective, single‑arm study was conducted at Beijing Cancer Hospital between May 2022 and May 2025. Patients received subcutaneous envafolimab (200 mg, day 1) and a continuous intravenous infusion of endostar (210 mg over 72 h) every 3 weeks until disease progression or unacceptable toxicity. Tumor responses were evaluated using RECIST v1.1, and adverse events (AEs) were graded according to CTCAE v5.0. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were estimated using the Kaplan-Meier method. A total of 20 patients, with a median age of 69 years, were enrolled in this study. The treatment demonstrated promising efficacy, achieving an objective response rate (ORR) of 30% and a disease control rate (DCR) of 60%. With a median follow-up of 21.8 months, the median progression-free survival (PFS) was 16.5 months, and the median overall survival (OS) was not reached. Furthermore, there were no reported cases of grade ≥ 3 treatment-related adverse events (TRAEs) or treatment-related deaths, indicating that the combination regimen was exhibited a favorable safety profile. The combination of envafolimab and endostar demonstrated promising efficacy and a manageable safety profile in patients with advanced NSCLC. Notably, it also exhibited preliminary clinical activity in the subgroup with disease progression following prior PD-1 blockade. These findings suggest that dual targeting with a PD-L1 inhibitor and anti-angiogenic therapy represents a viable strategy to potentially overcome immune resistance. Large-scale prospective studies are warranted to validate these clinical benefits and identify predictive biomarkers for treatment response.

PMID 43052868
阅读全文 →
PubMedHaematologica2026-11-19

Comment on: "Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab".

Rago Angela A, Zomparelli Marco M, Di Toritto Tommaso Caravita TC

PMID 43053702
阅读全文 →
PubMedAsian journal of anesthesiology2026-11-19

Comparative Study Between Analgesic Effects of Quadratus Lumborum Block (QLB) and Intravenous Analgesia in Patients Undergoing Nephrectomy.

Bodavula Venkata Naga Siva Sai Sandeep VNSSS, Chinthalapudi Mounika M, K Ragha Deepti RD

Nephrectomy is associated with significant postoperative pain due to surgical trauma and visceral manipulation. Intravenous opioids are commonly used for analgesia but may cause systemic adverse effects. This study compared postoperative analgesic outcomes between quadratus lumborum block (QLB) and conventional intravenous analgesia (IVA) in patients undergoing nephrectomy. This hospital-based observational study included 60 patients, with 30 patients in each group. Group I received QLB with 0.25% bupivacaine, while Group II received conventional IVA. Postoperative pain was assessed using the visual analogue scale (VAS) every two hours for 24 hours. Sedation was evaluated using the Modified Ramsay Sedation Score. Hemodynamic parameters, intraoperative fentanyl use, and postoperative tramadol and paracetamol consumption were recorded. Data were analyzed using SPSS v26.0. Intergroup comparisons were performed using independent t-tests. VAS scores were significantly lower in the QLB group during the first 8 postoperative hours ( P < 0.001). Intraoperative fentanyl (100.00 µg vs. 161.67 µg), postoperative tramadol (61.67 mg vs. 148.33 mg), and paracetamol consumption (2.23 g vs. 3.27 g) were lower in the QLB group. Time to first rescue analgesia was longer in the QLB group (4.52 hours vs. 0.43 hours; P = 0.001). Sedation scores were lower during the first 4 hours. Intraoperative hemodynamic parameters also differed between groups, although baseline mean arterial pressure was significantly lower in the QLB group. QLB was associated with lower early postoperative pain scores, reduced analgesic requirements, and longer time to first rescue analgesia compared with IVA. The observational design limits causal interpretation of these findings.

PMID 43053653
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多immune globulin intravenous